(PharmaNewsWire.Com, April 08, 2017 ) Seasonal Influenza Therapeutics Market analysis is provided for Global Seasonal Influenza Therapeutics Market including Landscape, Introduction and Key Marketed Products. Global prevalence of the disease has risen significantly in the past several decades, primarily due to an increase in exposure to UV light and/or sunlight. This has resulted in an increase in developmental interest about improving disease management, particularly in the advanced metastatic setting. Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies
Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infections rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.
Scope: The seasonal influenza Asia-Pacific market will be valued at $1.71 billion in 2022, growing from $1.24 billion in 2015 at a CAGR of 4.7%. Trivalent and quadrivalent vaccines dominate the seasonal influenza market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the seasonal influenza market? Do quadrivalent therapies show continuous growth, and are they facing any competition from trivalent therapies? How will available therapies be affected by upcoming pipeline therapies? The pipeline contains a range of molecule types and molecular targets, including those that are well established in seasonal influenza. Which molecular targets appear most frequently in the pipeline? Will the pipeline drugs fulfill the unmet needs of seasonal influenza market? Market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of quadrivalent therapies. How will the annual cost of therapy and market size vary between the five Asia-Pacific markets? Various drivers and barriers will influence the market over the forecast period. What barriers limit the uptake of premium-priced vaccines in the assessed countries? What factors are most likely to drive the market in these countries?
Reasons to buy: Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies. Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market. Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies. Predict COPD market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth. Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
